Industry News

Telemedicine in the Operating Room: The ‘New Normal’ for MedTech

12/28/2020

Excerpt from the Article: There is incredibly high demand for collaboration during medical procedures – whether it’s a Cardiologist advising a more junior physician on a complex procedure, a renowned surgeon training other colleagues on a technique, a medical device company rolling out a new product, or a medical device rep providing product support during…

Read More

HKU chemists develop a new drug discovery strategy for “undruggable” drug targets

12/28/2020

Excerpt from the Article: A research team led by Dr Xiaoyu LI from the Research Division for Chemistry, Faculty of Science, in collaboration with Professor Yizhou LI from School of Pharmaceutical Sciences, Chongqing University and Professor Yan CAO from School of Pharmacy, Second Military Medical University in Shanghai has developed a new drug discovery method…

Read More

Early data suggest wearables can catch some cases of Covid-19 before symptoms emerge

12/25/2020

Excerpt from the Article: The results of several ambitious studies testing wearables as early predictors of for Covid-19 are in — and they suggest that data from devices including Apple Watches, Fitbits, and Oura smart rings may be useful for flagging some infections in people before they even feel ill. Recently published research from ongoing…

Read More

Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

12/24/2020

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. Initial data show that…

Read More

Study shows incorporating telemedicine helps surgical practices

12/23/2020

Excerpt from the Article: STONY BROOK, NY, December 18, 2020 – A new study that records patient volume at Stony Brook Medicine’s Bariatric and Metabolic Weight Loss Center reveals that follow-up telehealth visits are highly effective during the COVID-19 pandemic. The study, published in the December issue of the Annals of Surgery, serves as an…

Read More

How does the brain project manage its learning?

12/22/2020

Excerpt from the Article: The famous patient Henry Molaison (long known as H.M.) suffered damage to his hippocampus after a surgical attempt to cure his epilepsy. As a result, he had anterograde amnesia, which meant that things he learned never made it past his short-term memory. Though his memories of childhood remained intact, H.M. might…

Read More

AI-supported test predicts eye disease three years before symptoms

12/21/2020

Excerpt from the Article: A pioneering new eye test, developed by scientists at UCL in collaboration with the Western Eye Hospital, London, may predict wet AMD, a leading cause of severe sight loss, three years before symptoms develop. Researchers hope their test could be used to identify the disease early enough so that treatment can…

Read More

PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors

12/18/2020

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of its Phase 1 clinical trial of LYT-200 for the potential treatment of metastatic solid tumors that are…

Read More

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

12/17/2020

Excerpt from the Press Release: SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical update on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate (ADC) targeting HER2 positive cancers. “As presented at the 2020…

Read More

CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)

12/16/2020

Excerpt from the Press Release: CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and Alnylam Pharmaceuticals, Inc. (“Alnylam”), the leading…

Read More